Detalhe da pesquisa
1.
RAS/RAFlandscape in monoclonal plasma cell conditions.
Blood
; 2024 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38643494
2.
Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes.
J Allergy Clin Immunol
; 153(1): 349-353.e4, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37633651
3.
KIR3DL2 contributes to the typing of acute adult T-cell leukemia and is a potential therapeutic target.
Blood
; 140(13): 1522-1532, 2022 09 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35687761
4.
Gene therapy for haemophilia A and B, from basic principles to clinical implementation: An illustrated review.
Haemophilia
; 30(1): 5-15, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38111029
5.
Histological characterization of liver involvement in systemic mastocytosis.
Liver Int
; 2024 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38554045
6.
Efficacy and safety of mammalian target of rapamycin inhibitors in systemic mastocytosis: A nationwide French pilot study.
Am J Hematol
; 99(6): 1095-1102, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38581211
7.
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Haematologica
; 108(10): 2774-2782, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37078253
8.
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.
Haemophilia
; 29(4): 1087-1094, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37347645
9.
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma.
Future Oncol
; 19(13): 887-895, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37212642
10.
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
N Engl J Med
; 380(22): 2104-2115, 2019 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31141632
11.
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
N Engl J Med
; 381(8): 727-738, 2019 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31433920
12.
A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.
Blood
; 135(18): 1531-1540, 2020 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32108228
13.
Emicizumab does not interfere with the activated clotting time.
Haemophilia
; 28(2): 362-366, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35060654
14.
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(11): 1582-1596, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34655533
15.
Poor outcome and high prevalence of invasive fungal infections in patients with adult T-cell leukemia/lymphoma exposed to zidovudine and interferon alfa.
Ann Hematol
; 100(11): 2813-2824, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34387741
16.
Unique inflammatory signature in haemophilic arthropathy: miRNA changes due to interaction between blood and fibroblast-like synoviocytes.
J Cell Mol Med
; 24(24): 14453-14466, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33159500
17.
Arsenic trioxide (As2O3) as a maintenance therapy for adult T cell leukemia/lymphoma.
Retrovirology
; 17(1): 5, 2020 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32199462
18.
NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study.
Gut
; 68(8): 1396-1405, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30448772
19.
Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial.
Br J Haematol
; 187(3): 319-327, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31218679
20.
Inflammation is predictive of outcome in Waldenström macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life study.
Haematologica
; 109(1): 325-330, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37584289